NASDAQ
BTTX

Better Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Better Therapeutics Inc Stock Price

Vitals

Today's Low:
$0.58
Today's High:
$0.6089
Open Price:
$0.599
52W Low:
$0.589
52W High:
$2.8
Prev. Close:
$0.586
Volume:
56717

Company Statistics

Market Cap.:
$23.16 million
Book Value:
-0.412
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$-674000
Profit Margin:
0%
Return on Assets TTM:
-89.08%
Return on Equity TTM:
-448.56%

Company Profile

Better Therapeutics Inc had its IPO on 2021-10-28 under the ticker symbol BTTX.

The company operates in the Healthcare sector and Biotechnology industry. Better Therapeutics Inc has a staff strength of 54 employees.

Stock update

Shares of Better Therapeutics Inc opened at $0.6 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.58 - $0.61, and closed at $0.58.

This is a -0.65% slip from the previous day's closing price.

A total volume of 56,717 shares were traded at the close of the day’s session.

In the last one week, shares of Better Therapeutics Inc have slipped by -4.87%.

Better Therapeutics Inc's Key Ratios

Better Therapeutics Inc has a market cap of $23.16 million, indicating a price to book ratio of 4.5838 and a price to sales ratio of 49559.4078.

In the last 12-months Better Therapeutics Inc’s revenue was $0 with a gross profit of $-674000 and an EBITDA of $-37697000. The EBITDA ratio measures Better Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Better Therapeutics Inc’s operating margin was 0% while its return on assets stood at -89.08% with a return of equity of -448.56%.

In Q1, Better Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Better Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-1.75 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Better Therapeutics Inc’s profitability.

Better Therapeutics Inc stock is trading at a EV to sales ratio of 74299.06 and a EV to EBITDA ratio of -0.6259. Its price to sales ratio in the trailing 12-months stood at 49559.4078.

Better Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$12.81 million
Total Liabilities
$13.64 million
Operating Cash Flow
$0
Capital Expenditure
$521000
Dividend Payout Ratio
0%

Better Therapeutics Inc ended 2024 with $12.81 million in total assets and $0 in total liabilities. Its intangible assets were valued at $12.81 million while shareholder equity stood at $-9833000.00.

Better Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $13.64 million in other current liabilities, 2000.00 in common stock, $-120860000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $6.07 million and cash and short-term investments were $6.07 million. The company’s total short-term debt was $5,539,000 while long-term debt stood at $9.00 million.

Better Therapeutics Inc’s total current assets stands at $8.44 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $2.51 million and inventory worth $0.

In 2024, Better Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $521000.

Comparatively, Better Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.58
52-Week High
$2.8
52-Week Low
$0.589
Analyst Target Price
$10

Better Therapeutics Inc stock is currently trading at $0.58 per share. It touched a 52-week high of $2.8 and a 52-week low of $2.8. Analysts tracking the stock have a 12-month average target price of $10.

Its 50-day moving average was $0.74 and 200-day moving average was $1.03 The short ratio stood at 0.8 indicating a short percent outstanding of 0%.

Around 5605% of the company’s stock are held by insiders while 494.6% are held by institutions.

Frequently Asked Questions About Better Therapeutics Inc

The stock symbol (also called stock or share ticker) of Better Therapeutics Inc is BTTX

The IPO of Better Therapeutics Inc took place on 2021-10-28

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
NILKAMAL LTD. (NILKAMAL)
$2398.75
-42.35
-1.73%
$685.65
-18.15
-2.58%
$0.01
0
0%
$0.98
-0.06
-5.77%
$1.04
0.15
+16.85%
$0.07
0
0%
$0.05
0
+0.42%
$24.9
-0.7
-2.73%
$246.8
-15.25
-5.82%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company’s lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company’s clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

Address

548 Market Street, San Francisco, CA, United States, 94104